Device Trial Radar · NCT05230524
DIAMOND AF Post-Approval Study
Last checked: Nov 20, 2026Latest source record: Jul 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
84
Actual
Start
Feb 28, 2022
Primary completion
Dec 17, 2025
Study completion Dec 17, 2025
Sponsor
- Lead sponsor
- Medtronic Cardiac Ablation SolutionsPublic (MDT)
- Sponsor type
- Industry
- First posted
- Feb 9, 2022
Design
- Study type
- Observational
- FDA-regulated device
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The DIAMOND AF Post Approval study is a prospective, global, multi-center, non-randomized, single-arm observational trial
Conditions
- Paroxysmal Atrial Fibrillation
Interventions
DiamondTemp™ Ablation SystemDevice
Pulmonary vein isolation will be performed with the DiamondTemp™ Ablation System
Primary outcomes
What the sponsor says the trial is designed to measure.
- Freedom from Atrial Fibrillation (AF) /Atrial Flutter (AFL) /Atrial Tachycardia (AT)Time frame: 36 month
- Freedom from Primary Safety EventsTime frame: 12 months
Locations
5 sites in 3 countries. Site status is shown where the registry gives one.
Florida Electrophysiology LLC
Winter Park, Florida
Centre Hospitalier de Pau - Hôpital François Mitterrand
Pau, France
Reunion University Hospital - Saint Pierre
Saint-Pierre, France
2 more study sites with a free account
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.